The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Celgene; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Kami J. Maddocks
Honoraria - Bayer; Novartis; Pharmacyclics; Teva
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
Sven De Vos
Consulting or Advisory Role - Bayer; Verastem
 
Roger M. Lyons
Employment - Texas Oncology
Leadership - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Avvie; Celgene; Genentech/Incyte; Gilead Sciences; Rigel; Takeda
 
William Jeffery Edenfield
Speakers' Bureau - Astellas Medivation; Novartis
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Celgene; Genentech; Pharmacyclics; TG Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Julie Vose
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Epizyme; Janssen Scientific Affairs; Karyopharm Therapeutics; Kite/Gilead; Legend Biotech; Miltenyi Biotec; Nordic Nanovector; Novartis; Roche; Sandoz; Vaniam Group; Verastem
Consulting or Advisory Role - Bio Connections
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Seagen (Inst)
 
Habte Aragaw Yimer
Consulting or Advisory Role - Amgen; Celgene; Epizyme; Seagen
Speakers' Bureau - AstraZeneca; Janssen
 
Helen Wei
Employment - Acerta Pharma
 
Edward M Chan
Employment - Acerta Pharma; Genentech/Roche
Stock and Other Ownership Interests - Acerta Pharma; Genentech/Roche; Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Priti Patel
Employment - AstraZeneca
Stock and Other Ownership Interests - Acerta Pharma; AstraZeneca
 
Christopher Di Simone
No Relationships to Disclose
 
Mitul Gandhi
No Relationships to Disclose
 
Jennifer Vaughn
No Relationships to Disclose
 
Kathryn Kolibaba
Employment - Compass Oncology
Honoraria - TG Therapeutics
Consulting or Advisory Role - Gilead Sciences
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Cell Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Novartis (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - TG Therapeutics
 
Bruce D. Cheson
Consulting or Advisory Role - Abbvie; Acerta Pharma; Bayer; Morphosys; Pharmacyclics/Janssen; Roche/Genentech; Sunesis Pharmaceuticals; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Gilead Sciences (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
 
Felipe Samaniego
Consulting or Advisory Role - Celgene